Background/Aims: The substantial improvement in survival of children with cancer has been achieved at the cost of late effects. We aimed to evaluate the endocrine outcome in survivors of childhood non-brain malignant solid tumors (NBMST). Methods: We performed a retrospective medical record review for medical history, clinical and laboratory data of survivors (n = 139) followed at the endocrine clinic of a tertiary medical center. Outcome measures were frequency and types of endocrine dysfunction and components of the metabolic syndrome. Results: Median follow-up time was 9.0 years (range 1.2-29.5 years). At least one endocrine abnormality was found in 44 patients (31.7%). Abnormalities included hypogonadism (11.5%), hypothyroidism (9.4%), short stature (9.4%), growth hormone deficiency (8.6%) and components of the metabolic syndrome (15.1%). Height SDS decreased significantly (p = 0.004) during follow-up, whereas body mass index SDS tended to increase. On logistic regression analysis, treatment with cranial irradiation (p = 0.003), local radiation (p = 0.042), or bone marrow transplantation (p = 0.0001), and older age at last visit (p < 0.001) were associated with a significantly higher hazard of an endocrinopathy. Conclusions: The high rate of late endocrine dysfunction among survivors of childhood NBMST highlights the need to optimize the follow-up at the late-effects clinics to identify endocrine problems and allow early and effective intervention.

1.
Robison LL, Green DM, Hudson M, Meadows AT, Mertrns AC, Packer RJ, et al: Long term outcomes of adult survivors of childhood cancer - results from the Childhood Cancer Study. Cancer 2005;104(suppl 11): 2557-2564.
2.
Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al: SEER Cancer Statistic Review 1975-2006. Bethesda, National Cancer Institute, 2009. http://seer.cancer.gov/csr/1975-2006/basedonNovember2008SEERdatasubmission; posted to the SEER web site.
3.
Kenney LB, Bradeen H, Kadan-Lottick NS, Diller L, Homans A, Schwartz CL: The current status of follow-up services for childhood cancer survivors, are we meeting goals and expectations: a report from the consortium for New England childhood cancer survivors. Pediatr Blood Cancer 2011;57:1062-1066.
4.
Long KA, Marsland AL: Family adjustment to childhood cancer: a systematic review. Clin Child Fam Psychol Rev 2011;14:57-88.
5.
Talvensaari KK, Lanning M, Tapanainen P, Knip M: Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 1996;81:3051-3055.
6.
Oeffinger KC, Buchanan GR, Eshelman DA, Denke MA, Andrews TC, Germak JA, et al: Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2001;23:424-430.
7.
Nuver J, Smit AJ, Postma A, Sleijfer DT, Gietema JA: The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev 2002;7372:195-214.
8.
Hudson MM, Mulrooney DA, Bowers DC, Sklar CA, Green DM, Donaldson SS, et al: High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol 2009;27:2405-2414.
9.
Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, et al: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-1076.
10.
Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G: Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc Health Risk Manag 2008;4:825-836.
11.
Woodward E, Jessop M, Glaser A, Stark D: Late effects in survivors of teenage and young adult cancer: does age matter? Ann Oncol DOI: 10.1093/annonc/mdr044.
12.
Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, et al: Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007;297:2705-2715.
13.
Roman J, Villaizan CJ, Garcia-Foncillas J, Salvador J, Sierrasesumaga L: Growth and growth hormone secretion in children with cancer treated with chemotherapy. J Pediatr 1997;131:105-112.
14.
Samuelsson BO, Marky I, Rosberg S, Albertsson-Wikland K: Growth and growth hormone secretion after treatment for childhood non-Hodgkin's lymphoma. Med Pediatr Oncol 1997;28:27-34.
15.
Davies HA, Didcock E, Didi M, Ogilvy-Stuart A, Wales JK, Shalet SM: Growth, puberty and obesity after treatment for leukaemia. Acta Paediatr 1995;411(suppl):45-50.
16.
Nysom K, Holm K, Michaelsen KF, Hertz H, Muller J, Molgaard C: Degree of fatness after treatment for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab 1999;84:4591-4596.
17.
Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-1732.
18.
Didi M, Didcock E, Davies HA, Ogilvy-Stuart AL, Wales JK, Shalet SM: High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 1995;127:63-67.
19.
Hoffman KE, Derdak J, Bernstein D, Reynolds JC, Avila NA, Gerber L, et al: Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 2008;50:341-346.
20.
van Santen HM, de Kraker J, Vulsma T: Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005;41:1767-1774.
21.
Kenney LB, Laufer MR, Grant FD, Grier H, Diller L: High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 2001;91:613-621.
22.
Wikström AM, Hovi L, Dunkel L, Saarinen-Pihkala UM: Restoration of ovarian function after chemotherapy for osteosarcoma. Arch Dis Child 2003;88:428-431.
23.
Kuczmarski RJ, Ogden CL, Grummer-Strawn LM: CDC growth charts: United States. Adv Data 2000;8:1-27.
24.
Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 1996;98:649-658.
25.
Rosenfield R: Puberty in the female and its disorders; in Sperling MA (ed): Pediatric Endocrinology, ed 2. Philadelphia, Elsevier Science, 2002, p 494.
26.
Styne DM: The testes: disorders of sexual differentiation and puberty in the male; in Sperling MA (ed): Pediatric Endocrinology, ed 2. Philadelphia, Elsevier Science, 2002, p 599.
27.
Daniels SR, Greer FR, the Committee on Nutrition: Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198-208.
28.
Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al: IDF Consensus Group. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007;8:299-230.
29.
Dixon WJ: BMDP Statistical Software. Los Angeles, University of California Press, 1993.
30.
Shalitin S, Gal M, Goshen Y, Cohen I, Yaniv I, Phillip M: Endocrine outcome in long-term survivors of childhood brain tumors. Horm Res Paediatr 2011;76:113-122.
31.
Patterson BC, Wasilewski-Masker K, Ryerson AB, Mertens A, Meacham L: Endocrine health problems detected in 519 patients evaluated in a pediatric cancer survivors program. J Clin Endocrinol Metab 2012;97:810-818.
32.
Bar Dayan Y, Elishkevits K, Grotto I, Goldstein L, Goldberg A, Shvarts S, et al: The prevalence of obesity and associated morbidity among 17-year-old Israeli conscripts. Public Health 2005;119:385-389.
33.
Livesey EA, Hindmarsh PC, Brook CG, Whitton AC, Bloom HJ, Tobias JS, et al: Endocrine disorders following treatment of childhood brain tumors. Br J Cancer 1990;61:622-625.
34.
Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H, et al: Cranial radiotherapy of childhood brain tumors: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clin Endocrinol 2000;53:191-197.
35.
Shalitin S, Phillip M, Stein J, Goshen Y, Carmi D, Yaniv I: Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant 2006;37:1109-1117.
36.
van Waas M, Neggers SJ, van der Lelij AJ, Pieters R, van den Heuvel- Eibrink MM: The metabolic syndrome in adult survivors of childhood cancer, a review. J Pediatr Hematol Oncol 2010;32:171-179.
37.
Miller TL, Lipsitz SR, Lopez-Mitnik G, Hinkle AS, Constine LS, Adams MJ, et al: Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010;19:2013-2022.
38.
Steinberger J, Sinaiko AR, Kelly AS, Leisenring WM, Steffen LM, Goodman P, et al: Cardiovascular risk and insulin resistance in childhood cancer survivors. J Pediatr 2012;160:494-499.
39.
Schmitz KH, Holtzman J, Courneya KS, Mâsse LC, Duval S, Kane R: Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2005;14:1588-1595.
40.
Garmey EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, et al: Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2008;26:4639-4645.
41.
Oudin C, Simeoni MC, Sirvent N, Contet A, Begu-Le Coroller A, Bordigoni P, et al: Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 2011;117:4442-4448.
42.
van Waas M, Neggers SJ, Pieters R, van den Heuvel-Eibrink MM: Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. Ann Oncol 2010;21:1121-1126.
43.
Ross JA, Oeffinger KC, Davies SM, Mertens AC, Langer EK, Kiffmeyer WR, et al: Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2004;22:3558-3562.
44.
Reilly JJ, Kelly A, Ness P, Dorosty AR, Wallace WH, Gibson BE, et al: Premature adiposity rebound in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 2001;86:2775-2778.
45.
Gleeson HK, Shalet SM: The impact of cancer therapy on the endocrine system in survivors of childhood brain tumors. Endocr Relat Cancer 2004;11:589-602.
46.
Green DM, Sklar CA, Boice JR JD, Mulvihill JJ, Whitton JA, Stovall M, et al: Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivors Study. J Clin Oncol 2009;27:2374-2381.
47.
Rivkees SA, Crawford JD: The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988;259:2123-2125.
48.
Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, et al: Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer 2013;60:1083-1094.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.